Congenital Hemolytic Anemia Overview

Save information for later
Sign Up

Learn About Congenital Hemolytic Anemia

View Main Condition: Anemia

What is the definition of Congenital Hemolytic Anemia?
Congenital hemolytic anemia is a genetic disorder in which there is a significant reduction in red blood cells in the blood that are fit to carry oxygen due to an abnormality in how the cells are formed. There are several types of congenital hemolytic anemias, including sickle cell disease (SCD), hereditary spherocytosis, and pyruvate kinase deficiency.
What are the symptoms of Congenital Hemolytic Anemia?
Symptoms of congenital hemolytic anemia may include fatigue, paleness, fever, mental confusion, dizziness, difficulty breathing on exertion, dark urine, yellowing of the skin and whites of eyes (jaundice), enlarged liver or spleen, kidney failure, pain in the extremities, heart murmur, and irregular heartbeat.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Congenital Hemolytic Anemia?
Treatment for congenital hemolytic anemia depends on the severity of the disorder and may include blood transfusions, corticosteroids, intravenous immune globulin (IVIG), blood exchange transfusion, splenectomy, and immunosuppressive therapy.
Who are the top Congenital Hemolytic Anemia Local Doctors?
Abdullah Kutlar
Elite in Congenital Hemolytic Anemia
Dr. Abdullah Kutlar
Hematology Oncology | Hematology | Oncology
Elite in Congenital Hemolytic Anemia
Dr. Abdullah Kutlar
Hematology Oncology | Hematology | Oncology

Wellstar Medical Group LLC

989 Saint Sebastian Way, 
Augusta, GA 
706-721-2171
Languages Spoken:
English, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Abdullah Kutlar is a Hematologist Oncology specialist and a Hematologist in Augusta, Georgia. Dr. Kutlar is rated as an Elite provider by MediFind in the treatment of Congenital Hemolytic Anemia. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemolytic Anemia, Congenital Hemolytic Anemia, and Bone Marrow Aspiration. Dr. Kutlar is currently accepting new patients.

Marilyn J. Telen
Elite in Congenital Hemolytic Anemia
Dr. Marilyn J. Telen
Hematology
Elite in Congenital Hemolytic Anemia
Dr. Marilyn J. Telen
Hematology

Duke Adult Comprehensive Sickle Cell Center - Clinic 2N

40 Duke Medicine Cir, 
Durham, NC 
919-684-6464
Experience:
52+ years
Languages Spoken:
English, French, Russian
See accepted insurances
Offers Telehealth

Marilyn Telen is a Hematologist in Durham, North Carolina. Dr. Telen has been practicing medicine for over 52 years and is rated as an Elite provider by MediFind in the treatment of Congenital Hemolytic Anemia. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.

 
 
 
 
Learn about our expert tiers
Learn More
Payal C. Desai
Elite in Congenital Hemolytic Anemia
Dr. Payal C. Desai
Hematology
Elite in Congenital Hemolytic Anemia
Dr. Payal C. Desai
Hematology

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Payal Desai is a Hematologist in Charlotte, North Carolina. Dr. Desai is rated as an Elite provider by MediFind in the treatment of Congenital Hemolytic Anemia. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Aspiration. Dr. Desai is currently accepting new patients.

View All Doctors
What are the latest Congenital Hemolytic Anemia Clinical Trials?
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Biological
Study Phase: Phase 3

Summary: This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemia
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemia
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Biological
Study Phase: Phase 3

Summary: This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).

View All Clinical Trials